Difficulty with activities of daily living often affect Alzheimer's patients, which is estimated to affect as many as 5.1 million Americans. These issues are among the most taxing burdens of the disease for caregivers, which total about 5.4 million family members and friends. New research from the faculty of Icahn School of Medicine at Mount Sinai working with Veterans Administration Medical Centers suggests that alpha tocepherol, fat-soluble Vitamin E and antioxidant, may slow functional decline (problems with daily activities such as shopping, preparing meals, planning, and traveling) in patients with mild-to-moderate Alzheimer's disease and decrease caregiver burden. There was no added benefit for memory and cognitive testing with the vitamin. The study is published online first in the Jan. 1 Journal of the American Medical Association.
"Since the cholinesterase inhibitors [galantamine, donepezil, rivastigmine], we have had very little to offer patients with mild-to-moderate dementia," said Mary Sano, PhD, trial co-investigator, and professor in the department of psychiatry, Icahn School of Medicine at Mount Sinai, and director of research at the James J. Peters Veteran's Administration Medical Center, Bronx, New York. "This trial showed that vitamin E delays progression of functional decline by 19% per year, which translates into 6.2 months benefit over placebo."
The finding is valuable because vitamin E is easy to purchase at local drugstores and it is also inexpensive. The clinical trial investigators believe it can be recommended as a treatment strategy, based on the double-blind randomized controlled trial.
The Veteran's Administration Cooperative Randomized Trial of Vitamin E and memantine in Alzheimer's Disease (TEAM-AD examined the effects of vitamin E 2,000 IU/d, 20 mg/d of memantine, the combination, or placebo on Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory Score. Cognitive, neuropsychiatric, functional, and caregiver measures were secondary outcomes. A group of 613 patients with mild to moderate Alzheimer's disease were in the study, which was launched in August 2007 and finished in September 2012 at 14 Veterans Affairs Medical Centers.
Dr. Sano previously led a study on vitamin E in patients with moderately severe Alzheimer's disease. She found that the vitamin slowed disease progression in this group of patients as well.
Kenneth Davis, MD, Chief Executive Officer and President of the Mount Sinai Health System and Gustave L. Levy Distinguished Professor, applauded the study. "This study is the first to show an added benefit for vitamin E in mild-to-moderate disease," he said. "Now that we have a strong clinical trial showing that vitamin E slows functional decline and reduces the burdens on caregivers, vitamin E should be offered to patients with mild-to-moderate Alzheimer's disease." Research by Dr. Davis and colleagues contributed to the establishment of conventional medical therapies for Alzheimer's disease.
Explore further: Semagacestat doesn't improve cognitive status in Alzheimer's
More information: doi:10.l001/jama.2013.282834 and doi:10.l001/jama.2013.282835
Medical Xpress on facebook
Related Stories
Evidence lacking for efficacy of memantine in treating mild Alzheimer's disease
Apr 11, 2011
An analysis of studies involving the drug memantine finds a lack of evidence for benefit when the drug is used to treat patients with mild Alzheimer disease, according to a report posted online today that will appear in the ...
Vitamin B derivative helps diabetics with mild kidney disease
Oct 27, 2011
A vitamin B6 derivative may help slow or prevent the progression of mild kidney disease in patients with diabetes, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN) ...
Clinical trial examines antioxidant effects for Alzheimer's disease on cerebrospinal fluid biomarkers
Mar 19, 2012
An antioxidant combination of vitamin E, vitamin C and α-lipoic acid (E/C/ALA) was not associated with changes in some cerebrospinal fluid biomarkers related to Alzheimer disease in a randomized controlled trial, according ...
Vitamin B supplementation did not slow cognitive decline in patients with Alzheimer disease
Oct 14, 2008
High-dose vitamin B supplementation for patients with mild to moderate Alzheimer disease did not slow the rate of cognitive decline, according to a study in the October 15 issue of JAMA.
Semagacestat doesn't improve cognitive status in Alzheimer's
Jul 25, 2013
(HealthDay)—For patients with Alzheimer's disease, treatment with the small-molecule γ-secretase inhibitor semagacestat does not improve cognitive status and is associated with worsening of cognitive function, ...
Recommended for you
Some with Alzheimer's find care in far-off nations
Dec 30, 2013
Residents of this facility for people with Alzheimer's disease toss around a yellow ball and laugh under a cascade with their caregivers, in a swimming pool ringed by palm trees and wind chimes. Susanna Kuratli, ...
Researchers identify variation in gene PLD3 can increase risk of late-onset Alzheimer’s disease
Dec 24, 2013
(Medical Xpress)—A new study, part-funded by the Medical Research Council (MRC), the Wellcome Trust and Alzheimer's Research UK, has shown that a fault in a gene called phospholipase D3 (PLD3) can contribute to the overproduction ...
Alzheimer's prevention initiative marks milestone
Dec 23, 2013
The Alzheimer's Prevention Initiative (API) trial in cognitively healthy individuals has reached a significant milestone with the first participants in Colombia receiving doses of an experimental anti-amyloid antibody, crenezumab ...
Study shows where Alzheimer's starts and how it spreads
Dec 22, 2013
Using high-resolution functional MRI (fMRI) imaging in patients with Alzheimer's disease and in mouse models of the disease, Columbia University Medical Center (CUMC) researchers have clarified three fundamental ...
During the holidays, keep an eye on the elderly for symptoms of Alzheimer's
Dec 20, 2013
When Deborah Bell's father was diagnosed with gallbladder cancer seven years ago, she knew something was off about her mother, Rosa.
Living at home with dementia
Dec 19, 2013
Most people with dementia who live at home have multiple unmet health and welfare needs, any number of which could jeopardize their ability to remain home for as long as they desire, new Johns Hopkins research suggests.
User comments
© Medical Xpress 2011-2013, Science X network
Difficulty with activities of daily living often affect Alzheimer's patients, which is estimated to affect as many as 5.1 million Americans. These issues are among the most taxing burdens of the disease for caregivers, which total about 5.4 million family members and friends. New research from the faculty of Icahn School of Medicine at Mount Sinai working with Veterans Administration Medical Centers suggests that alpha tocepherol, fat-soluble Vitamin E and antioxidant, may slow functional decline (problems with daily activities such as shopping, preparing meals, planning, and traveling) in patients with mild-to-moderate Alzheimer's disease and decrease caregiver burden. There was no added benefit for memory and cognitive testing with the vitamin. The study is published online first in the Jan. 1 Journal of the American Medical Association.
"Since the cholinesterase inhibitors [galantamine, donepezil, rivastigmine], we have had very little to offer patients with mild-to-moderate dementia," said Mary Sano, PhD, trial co-investigator, and professor in the department of psychiatry, Icahn School of Medicine at Mount Sinai, and director of research at the James J. Peters Veteran's Administration Medical Center, Bronx, New York. "This trial showed that vitamin E delays progression of functional decline by 19% per year, which translates into 6.2 months benefit over placebo."
The finding is valuable because vitamin E is easy to purchase at local drugstores and it is also inexpensive. The clinical trial investigators believe it can be recommended as a treatment strategy, based on the double-blind randomized controlled trial.
The Veteran's Administration Cooperative Randomized Trial of Vitamin E and memantine in Alzheimer's Disease (TEAM-AD examined the effects of vitamin E 2,000 IU/d, 20 mg/d of memantine, the combination, or placebo on Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory Score. Cognitive, neuropsychiatric, functional, and caregiver measures were secondary outcomes. A group of 613 patients with mild to moderate Alzheimer's disease were in the study, which was launched in August 2007 and finished in September 2012 at 14 Veterans Affairs Medical Centers.
Dr. Sano previously led a study on vitamin E in patients with moderately severe Alzheimer's disease. She found that the vitamin slowed disease progression in this group of patients as well.
Kenneth Davis, MD, Chief Executive Officer and President of the Mount Sinai Health System and Gustave L. Levy Distinguished Professor, applauded the study. "This study is the first to show an added benefit for vitamin E in mild-to-moderate disease," he said. "Now that we have a strong clinical trial showing that vitamin E slows functional decline and reduces the burdens on caregivers, vitamin E should be offered to patients with mild-to-moderate Alzheimer's disease." Research by Dr. Davis and colleagues contributed to the establishment of conventional medical therapies for Alzheimer's disease.
Explore further: Semagacestat doesn't improve cognitive status in Alzheimer's
More information: doi:10.l001/jama.2013.282834 and doi:10.l001/jama.2013.282835
Medical Xpress on facebook
Related Stories
Evidence lacking for efficacy of memantine in treating mild Alzheimer's disease
Apr 11, 2011
An analysis of studies involving the drug memantine finds a lack of evidence for benefit when the drug is used to treat patients with mild Alzheimer disease, according to a report posted online today that will appear in the ...
Vitamin B derivative helps diabetics with mild kidney disease
Oct 27, 2011
A vitamin B6 derivative may help slow or prevent the progression of mild kidney disease in patients with diabetes, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN) ...
Clinical trial examines antioxidant effects for Alzheimer's disease on cerebrospinal fluid biomarkers
Mar 19, 2012
An antioxidant combination of vitamin E, vitamin C and α-lipoic acid (E/C/ALA) was not associated with changes in some cerebrospinal fluid biomarkers related to Alzheimer disease in a randomized controlled trial, according ...
Vitamin B supplementation did not slow cognitive decline in patients with Alzheimer disease
Oct 14, 2008
High-dose vitamin B supplementation for patients with mild to moderate Alzheimer disease did not slow the rate of cognitive decline, according to a study in the October 15 issue of JAMA.
Semagacestat doesn't improve cognitive status in Alzheimer's
Jul 25, 2013
(HealthDay)—For patients with Alzheimer's disease, treatment with the small-molecule γ-secretase inhibitor semagacestat does not improve cognitive status and is associated with worsening of cognitive function, ...
Recommended for you
Some with Alzheimer's find care in far-off nations
Dec 30, 2013
Residents of this facility for people with Alzheimer's disease toss around a yellow ball and laugh under a cascade with their caregivers, in a swimming pool ringed by palm trees and wind chimes. Susanna Kuratli, ...
Researchers identify variation in gene PLD3 can increase risk of late-onset Alzheimer’s disease
Dec 24, 2013
(Medical Xpress)—A new study, part-funded by the Medical Research Council (MRC), the Wellcome Trust and Alzheimer's Research UK, has shown that a fault in a gene called phospholipase D3 (PLD3) can contribute to the overproduction ...
Alzheimer's prevention initiative marks milestone
Dec 23, 2013
The Alzheimer's Prevention Initiative (API) trial in cognitively healthy individuals has reached a significant milestone with the first participants in Colombia receiving doses of an experimental anti-amyloid antibody, crenezumab ...
Study shows where Alzheimer's starts and how it spreads
Dec 22, 2013
Using high-resolution functional MRI (fMRI) imaging in patients with Alzheimer's disease and in mouse models of the disease, Columbia University Medical Center (CUMC) researchers have clarified three fundamental ...
During the holidays, keep an eye on the elderly for symptoms of Alzheimer's
Dec 20, 2013
When Deborah Bell's father was diagnosed with gallbladder cancer seven years ago, she knew something was off about her mother, Rosa.
Living at home with dementia
Dec 19, 2013
Most people with dementia who live at home have multiple unmet health and welfare needs, any number of which could jeopardize their ability to remain home for as long as they desire, new Johns Hopkins research suggests.
User comments
© Medical Xpress 2011-2013, Science X network
0 comments:
Post a Comment